⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534120 | 1.00 | — | — | |
| SCHEMBL3595833 | 1.00 | — | — | |
| SCHEMBL18366119 | 0.86 | — | — | |
| SCHEMBL16454411 | 0.78 | — | — | |
| SCHEMBL4951040 | 0.74 | — | — | |
| SCHEMBL12213012 | 0.74 | — | — | |
| SCHEMBL9282454 | 0.72 | — | — | |
| SCHEMBL3982749 | 0.71 | — | — | |
| SCHEMBL28816058 | 0.70 | — | — | |
| SCHEMBL19809007 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522615-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546607-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250066356-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023220238-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220238-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| EP-0462813-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-10-25 | — | — | EP | disclosed |
| US-5403859-A | PHENYLENE-CYCLIC ETHER COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-04 | — | — | US | disclosed |
| US-5373007-A | Lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-12-13 | — | — | US | disclosed |
| US-5321025-A | Inhibitors of 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-14 | — | — | US | disclosed |
| EP-0375404-B1 | Heterocyclic derivatives | ICI PLC (GB) | 1994-02-09 | — | — | EP | disclosed |
| US-5234950-A | Antiallergens, antiinflammatory agents; cardiovascular disorders, antiarthritic | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-10 | — | — | US | disclosed |
| US-5217969-A | Antiinflammatory, antiulcer agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |